GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.79 3.47

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.78

Maxim

1.79

Indicatori cheie
By Trading Economics
Venit	2.3M -18M
Vânzări	-1.9M -193K
Marjă de profit	9,174.093
Angajați	116
EBITDA	1.5M -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+566.49% upside

Dividende
By Dow Jones
Următoarele câștiguri	8 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-78M 557M
Deschiderea anterioară	-1.68
Închiderea anterioară	1.79

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 22:17 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Câștiguri

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Achiziții, Fuziuni, Preluări

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Câștiguri

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Câștiguri

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Câștiguri

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Câștiguri

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Câștiguri

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Câștiguri

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

566.49% sus

Prognoză pe 12 luni

Medie 12.33 USD 566.49%

Maxim 22 USD

Minim 8 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.